Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 2
1967 4
1968 4
1969 4
1970 1
1971 9
1972 10
1973 15
1974 20
1975 39
1976 42
1977 43
1978 38
1979 61
1980 52
1981 58
1982 55
1983 63
1984 84
1985 85
1986 78
1987 74
1988 101
1989 133
1990 154
1991 149
1992 177
1993 183
1994 185
1995 216
1996 250
1997 246
1998 229
1999 221
2000 283
2001 255
2002 315
2003 324
2004 288
2005 336
2006 349
2007 329
2008 348
2009 411
2010 481
2011 546
2012 624
2013 618
2014 617
2015 668
2016 613
2017 657
2018 685
2019 716
2020 715
2021 654
2022 340
2023 290
2024 174

Text availability

Article attribute

Article type

Publication date

Search Results

13,008 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Adult Acute Myeloid Leukemia with Maturation"
Page 1
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Heuser M, et al. Ann Oncol. 2020 Jun;31(6):697-712. doi: 10.1016/j.annonc.2020.02.018. Epub 2020 Mar 17. Ann Oncol. 2020. PMID: 32171751 Free article. No abstract available.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Uy GL, et al. Blood. 2021 Feb 11;137(6):751-762. doi: 10.1182/blood.2020007732. Blood. 2021. PMID: 32929488 Free PMC article. Clinical Trial.
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). ...This paper reports the results of a multicenter, open-label, phase 1/2 stud …
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failu …
De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. Sasaki K, et al. Cancer. 2021 Jun 15;127(12):2049-2061. doi: 10.1002/cncr.33458. Epub 2021 Apr 5. Cancer. 2021. PMID: 33818756 Free article.
BACKGROUND: Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML). METHODS: The authors identified 29,107 patients who were diagnosed with de novo AML between …
BACKGROUND: Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of …
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. Dombret H, et al. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. Blood. 2015. PMID: 25987659 Free PMC article. Clinical Trial.
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age 65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Before rando …
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 48 …
Tetraploidy/near-tetraploidy acute myeloid leukemia.
Huang L, Wang SA, DiNardo C, Li S, Hu S, Xu J, Zhou W, Goswami M, Medeiros LJ, Tang G. Huang L, et al. Leuk Res. 2017 Feb;53:20-27. doi: 10.1016/j.leukres.2016.11.016. Epub 2016 Dec 2. Leuk Res. 2017. PMID: 27951415
A tetraploid/near tetraploid (T/NT) karyotype is a rare finding in acute myeloid leukemia (AML). Here we report 38 AML patients with a T/NT karyotype, including 26 men and 12 women with a median age of 65 years. ...Distinction of complex versus non-complex T/ …
A tetraploid/near tetraploid (T/NT) karyotype is a rare finding in acute myeloid leukemia (AML). Here we report 38 AML …
Acute myeloid leukemia in adolescents and young adults: challenging aspects.
Ofran Y, Rowe JM. Ofran Y, et al. Acta Haematol. 2014;132(3-4):292-7. doi: 10.1159/000360200. Epub 2014 Sep 10. Acta Haematol. 2014. PMID: 25228554 Review.
Treating adolescents and young adults (AYAs) diagnosed with cancer is a challenge. Acute myeloid leukemia (AML) which is usually diagnosed in a previously healthy kid, requiring immediate aggressive chemotherapy, brings difficulties and conflicts assoc …
Treating adolescents and young adults (AYAs) diagnosed with cancer is a challenge. Acute myeloid leukemia (AML) …
Frontline treatment of acute myeloid leukemia in adults.
Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Tamamyan G, et al. Crit Rev Oncol Hematol. 2017 Feb;110:20-34. doi: 10.1016/j.critrevonc.2016.12.004. Epub 2016 Dec 11. Crit Rev Oncol Hematol. 2017. PMID: 28109402 Free PMC article. Review.
Recent years have highlighted significant progress in understanding the underlying genetic and epigenetic signatures of acute myeloid leukemia(AML). Most importantly, novel chemotherapy and targeted strategies have led to improved outcomes in selected genetic …
Recent years have highlighted significant progress in understanding the underlying genetic and epigenetic signatures of acute myel …
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
Fabiani E, Cicconi L, Nardozza AM, Cristiano A, Rossi M, Ottone T, Falconi G, Divona M, Testi AM, Annibali O, Castelli R, Lazarevic V, Rego E, Montesinos P, Esteve J, Venditti A, Della Porta M, Arcese W, Lo-Coco F, Voso MT. Fabiani E, et al. Cancer Med. 2021 Jun;10(12):3839-3847. doi: 10.1002/cam4.3904. Epub 2021 May 27. Cancer Med. 2021. PMID: 34042280 Free PMC article.
BACKGROUND: The ZBTB16-RARA fusion gene, resulting from the reciprocal translocation between ZBTB16 on chromosome 11 and RARA genes on chromosome 17 [t(11;17)(q23;q21)], is rarely observed in acute myeloid leukemia (AML), and accounts for about 1% of retinoic …
BACKGROUND: The ZBTB16-RARA fusion gene, resulting from the reciprocal translocation between ZBTB16 on chromosome 11 and RARA genes on chrom …
Acute myeloid leukemia in the elderly: therapeutic options and choice.
Webster JA, Pratz KW. Webster JA, et al. Leuk Lymphoma. 2018 Feb;59(2):274-287. doi: 10.1080/10428194.2017.1330956. Epub 2017 Jun 2. Leuk Lymphoma. 2018. PMID: 28573892 Free PMC article. Review.
Acute myeloid leukemia (AML) therapies are rapidly evolving with novel targeted therapies showing high-level responses in a notoriously difficult to treat group of patients - the elderly and unfit. ...
Acute myeloid leukemia (AML) therapies are rapidly evolving with novel targeted therapies showing high-level responses …
Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
Winer ES. Winer ES. Hematol Oncol Clin North Am. 2020 Apr;34(2):449-463. doi: 10.1016/j.hoc.2019.11.003. Epub 2020 Jan 7. Hematol Oncol Clin North Am. 2020. PMID: 32089222 Review.
Secondary acute myeloid leukemia (sAML) is a complex diagnosis that includes AML caused by either an antecedent hematologic disease (AML-AHD) or from previous treatment with chemotherapy or radiation. This disease carries a poor prognosis and is histor …
Secondary acute myeloid leukemia (sAML) is a complex diagnosis that includes AML caused by either an antecedent hematol …
13,008 results
You have reached the last available page of results. Please see the User Guide for more information.